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ABSTRACT
Objective: To describe clinical data of children and ado-
lescents with portal hypertension, during with and without 
liver cirrhosis, treated with octreotide during episodes of 
acute upper gastrointestinal bleeding. 
Methods: Retrospective and descriptive study of 26 
episodes of gastrointestinal bleeding in 17 patients (mean 
age: 8.6 years; range: seven months to 18.9 years) assisted 
at a tertiary university hospital from 1996 to 2006. Portal 
hypertension diagnosis was based on ultrasonography. Liver 
cirrhosis was confirmed by histology and hepatic function 
was classified according the Child-Pugh score. 
Results: Portal hypertension etiology was extra-hepatic 
portal vein obstruction in 11/17 (65%) patients and cirrhosis in 
6/17 (35%). Bleeding was controlled in 14/17 (82%) patients. 
Octreotide infusion requirement was similar in cirrhotic and 
non-cirrhotic patients, but the decline in hemoglobin levels 
and the requirement of blood transfusions were greater but not 
significant in cirrhotic patients. The patients’ responses were 
similar regardless of drug infusion strategy. Whether it included 
a loading dose or not. Treatment failure was observed mainly 
among cirrhotic patients (33%). Hyperglycemia was the only 
side effect detected during octreotide infusion.
Conclusions: Octreotide administration in children and 
adolescents with digestive bleeding due to portal hyper-
tension was safe and effective in order to control the acute 
episode of bleeding, regardless of the etiology of portal 
hypertension and infusion strategy.
Key-words: octreotide; gastrointestinal bleeding; hyper-
tension, portal; child; adolescent.
RESUMO
Objetivo: Descrever a evolução clínica dos episódios de 
hemorragia digestiva em crianças portadoras de hipertensão 
portal, com e sem cirrose, tratadas com octreotida. 
Métodos: Estudo retrospectivo e descritivo de 26 epi-
sódios de sangramento digestivo em 17 pacientes (média 
de idade: 8,6 anos; variação: sete meses a 18,9 anos), no 
período de 1998 a 2006, num hospital terciário universitá-
rio. O diagnóstico de hipertensão portal foi estabelecido por 
ultrassonografia e a cirrose foi confirmada pela histologia e 
classificada quanto à gravidade pelo escore de Child-Pugh. 
Resultados: As causas da hipertensão portal foram: obs-
trução extra-hepática da veia porta em 11/17 casos (65%) 
e cirrose hepática em 6/17 (35%). O sangramento foi con-
trolado em 14/17 pacientes (82%). O tempo de infusão da 
droga necessário para controle do sangramento foi semelhante 
entre cirróticos e não cirróticos, mas o declínio nos níveis de 
hemoglobina, o volume transfusional requerido e o tempo de 
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internação foram maiores nos pacientes com cirrose, embora 
sem diferença estatística. Essas mesmas variáveis não se mo-
dificaram em relação aos dois diferentes esquemas de infusão 
da droga: com dose de ataque ou iniciando com dose de 
manutenção. Insucesso terapêutico foi observado com maior 
frequência entre os pacientes cirróticos (33%). Hiperglicemia 
foi o único efeito colateral detectado durante a infusão. 
Conclusões: A administração de octreotida em crianças e 
adolescentes com sangramento digestivo por hipertensão portal 
foi segura e efetiva no controle do sangramento agudo, indepen-
dente da causa da hipertensão portal e do esquema de infusão. 
Palavras-chave: octreotida; hemorragia digestiva; hiper-
tensão portal; criança; adolescente.
RESUMEN
Objetivo: Describir la evolución clínica de los episodios 
de hemorragia digestiva en niños portadores de hipertensión 
portal, con y sin cirrosis, tratados con octreotide. 
Métodos: Estudio retrospectivo y descriptivo de 26 epi-
sodios de sangramiento digestivo en 17 pacientes (promedio 
de edad 8,6 años, variación de 7 meses a 18,9 años), en el 
periodo de 1998 a 2006, en un hospital terciario universita-
rio. El diagnóstico de hipertensión portal fue establecido por 
ultrasonografía y la cirrosis fue confirmada por la histología y 
clasificada respecto a la gravedad por el escore Child-Pugh.
Resultados: Las causas de la hipertensión portal fueron 
obstrucción extrahepática de la vena porta en 11/17 casos 
(64,7%) y cirrosis hepática en 6/17 (35,3%). El sangramiento 
fue controlado en 14/17 pacientes (82,3%).  El tiempo de 
infusión de la droga necesario para control del sangramiento 
fue semejante entre cirróticos y no cirróticos, pero la caída 
en los niveles de hemoglobina, el volumen transfusional 
requerido y el tiempo de internación fueron superiores en 
los pacientes con cirrosis, aunque sin diferencia estadística. 
Esas mismas variables no se modificaron respecto a los dos 
distintos esquemas de infusión de la droga: con dosis de 
ataque o iniciando con dosis de mantenimiento. Fracaso 
terapéutico fue observado con mayor frecuencia entre los 
pacientes cirróticos (33,3%). Hiperglucemia fue el único 
efecto secundario detectado durante la infusión. 
Conclusiones: La administración de octreotide en niños 
y adolescentes con sangramiento digestivo por hipertensión 
portal fue segura y efectiva en el control del sangramiento 
agudo, independiente de la causa de la hipertensión portal 
y del esquema de infusión. 
Palabras clave: octreotide; hemorragia digestiva; hiper-
tensión portal; niños; adolescentes.
Introduction
Extrahepatic portal vein obstruction due to thrombosis is 
the most common cause of non-cirrhotic portal hypertension 
and biliary atresia is the more prevalent cause of cirrhosis(1).
Gastrointestinal bleeding from esophageal varices is the 
main cause of morbidity in patients with portal hyperten-
sion, bleeding recurrence is very high and mortality varies 
from 30 to 50%(2). During acute bleeding, in addition to 
measures of hemodynamic support, endoscopic treatment 
(sclerotherapy, band ligation, tissue adhesives such cyano-
acrylate) and specific drugs such as octreotide and somatosta-
tin are used for controlling bleeding.
Octreotide is a synthetic somatostatin that has been shown 
to reduce splanchnic blood flow in healthy volunteers and 
hepatic venous pressure in cirrhotic patients(3,4). Thus, it 
has been used for variceal bleeding. This drug has a marked 
clinical importance for patients awaiting endoscopy for 
esophageal varices diagnosis and treatment, for patients pre-
senting voluminous bleedings that impair visibility during 
the endoscopy, and for patients under increased rebleeding 
risk and who require the drug hypotensive effect for some 
days(5). Few studies have focused the use of octreotide in 
pediatric patients.
This study aimed to describe clinical data in children 
and adolescents with portal hypertension, with and without 
cirrhosis, who were treated with octreotide during acute 
gastrointestinal bleeding, and to evaluate eventual differ-
ences between the use or not of a bolus dose.
Method
Twenty patients were seen between March 1998 and De-
cember 2006 at the University Hospital in Faculty of Medical 
Sciences, Unicamp. Patients aged 7 months up to 18 years. All 
had portal hypertension diagnosis based on ultrasonographic 
criteria, presented upper gastrointestinal bleeding and received 
octreotide to control acute bleeding episodes. Three patients 
were excluded because their records were incomplete.
A retrospective and descriptive study was conducted. 
Patients were classified as cirrhotic or non-cirrhotic. The 
diagnosis of cirrhosis was based on histological data. Ultra-
sound was performed using a Toshiba Power Vision 6000 
apparatus equipped with 3.75-MHz sectorial and 5-MHz 
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linear transducers. The following parameters were evaluated 
in order to diagnose portal hypertension:  splenomegaly, 
gallbladder wall thickness, small omentum thickness close 
to the venous ligament, small omentum/aorta ratio, and 
presence of splenorenal shunt(6-9).
The Child-Pugh score(10) was used to determine the sever-
ity of liver disease in cirrhotic patients. The following pa-
rameters were evaluated: serum albumin and bilirubin levels, 
prothrombin time, presence of ascites and encephalopathy. 
According to the routine of the service, the presence of co-
agulopathy and thrombocytopenia was investigated by INR 
measurement and platelet count. Vitamin K, fresh frozen 
plasma and platelets were replaced as needed. Requirement 
of blood transfusion was recorded.
The origin of bleeding identified by endoscopy was 
registered. If In the source could not be identified, the 
site of bleeding was classified as indeterminate. Associ-
ated endoscopic treatment was also recorded. Endoscopy 
was performed with a Pentax or Olympus videoendoscope. 
Sclerotherapy or band ligation was indicated in patients 
with active bleeding of esophageal varices and/or bleeding 
of medium and large size esophageal varices even in the 
absence of active bleeding. Cyanoacrylate was administered 
in some cases of bleeding from gastric varices.
The variables related to octreotide treatment were 
evaluated: dose, duration and side effects. Patients re-
ceived a continuous intravenous infusion of 1-2µg/kg/h 
after an intravenous bolus dose (1µg/kg). The bolus 
administration was not universal. The criteria for the 
indication and duration of treatment were individually 
determined. The hospital stay in order to control bleed-
ing was also recorded.
Rebleeding and treatment failure were defined as a new 
episode of bleeding, accompanied by a drop in hemoglobin 
levels during treatment or up to 15 days after the end of the 
last octreotide infusion. Control of glycemia, blood pressure 
and symptoms were performed in order to detect possible 
adverse effects during octreotide infusion. 
Descriptive statistical analysis was performed, includ-
ing measures of position and dispersion for continuous 
variables and frequency tables for categorical variables. 
Fisher’s exact test was used to compare proportions. 
Continuous or ordinal variables were compared by Mann-
Whitney test. A level of significance of 5% was adopted. 
All analyses were performed using the SPSS for Windows 
program, version 7.5. This study was approved by the 
Ethical Committee of the University.
Results
Twenty-six episodes of upper gastrointestinal bleeding 
due to portal hypertension occurred in 17 patients between 
March 1998 and December 2006. Patients age ranged from 
0.56 to 18.9 years (mean: 8.64 and median: 7.91 years). The 
characteristics of the 26 upper gastrointestinal bleeding 
episodes are showed in Table 1.
Among the 17 patients, 8 (47.1%) were males; 6 (35.3%) 
had portal hypertension associated with cirrhosis, and 11 
(64.7%) s presented obstruction of the extrahepatic portal 
vein with normal liver function (associated with congenital 
hepatic fibrosis in one patient and with hepatoportal sclerosis 
in another).
Among the 26 bleeding episodes, six occurred were ob-
served in cirrhotic patients and 20 in non-cirrhotic patients. 
Propranolol was used on the occasion of bleeding as primary 
prophylaxis in 4/26 (15.4 %) episodes and as secondary 
prophylaxis in 7/26 (26.9%). 
 Patients undergone endoscopy in all bleeding episodes. 
Octreotide was already being used by the patients on the 
occasion of the exam in 13/26 (50%) episodes. Only 5/26 
(19.2%) episodes were characterized as active bleeding at 
the time of endoscopy, with octreotide already being used 
in 2 episodes. The site of bleeding was identified in 16/26 
(61.5%) episodes: esophageal varices in 9, gastric varices in 
3 and hypertensive gastropathy in 4. Endoscopic treatment 
was performed during 15/26 (57.7%) episodes: sclerotherapy 
(n=6) and band ligation (n=6) for esophageal varices and 
Table 1 - Clinical data from 26 upper gastrointestinal blee-
ding episodes in 17 children and adolescents followed in a 
university hospital
n (%)
Previous history of gastrointestinal 
bleeding
15 (57.7)
Propranolol previous use 11 (42.3)
Primary prophylaxis 4/11
Secondary prophylaxis 7/11
Previous sclerotherapy 15(57.3)
Previous band ligation 0
Site of bleeding
 Esophageal varices 9 (34.6)
 Gastric varices 3 (11.5)
 Hypertensive gastropathy 4 (15.4)
 Indeterminate 10 (38.4)
Coagulopathy 16 (61.5)
Thrombocytopenia 16 (61.5)
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cyanoacrylate (n=2) for the gastric varices. Sclerotherapy 
and cyanoacrylate were concomitantly applied during one 
of the episodes (Table 1).
A bolus dose of octreotide (ranged from 0.5 to 2.63µg/kg; 
mean: 1.19; median: 1µg/kg, P25/P75: 0.88/1.59) was ad-
ministered during 20 of the 26 episodes. In the other cases, 
only a maintenance dose was infused. Some patients’ weight 
was similar to adults weight so they received the maximum 
dose established by our protocol, conversely, in some cases 
the dose was lower than 1mcg/kg. The maintenance dose 
ranged from 0.44 to 1.43µg/kg/h (mean: 0.89, median: 
0.92µg/kg/h, P25/P75: 0.73/1.00). The mean duration of 
treatment was 3.1 days (median: 3 days, P25/P75: 2.0/4.0) 
and the median of hospitalization was 6 days (P25/P75: 
4.7/9.0). All patients received a proton pump inhibitor or H2 
inhibitor during bleeding. Vitamin K replacement therapy 
was indicated in 16/26 (61.5%) episodes.
Blood transfusion was performed in 17/26 (65.4%) bleed-
ing episodes, with the median hemoglobin drop of 3.27mg/
dl (ranging from 0.74 to 6.50mg/dl). The mean transfusion 
volume was 23.8mL/kg of packed red blood cells (median: 
16.4mL/kg, P25/P75: 10.84/30.3).
Hyperglycemia was the only side effect observed during 5 
(22.7%) of 22 episodes. In all cases, hyperglycemia was reversed 
by gradual reduction of the octreotide dose without the need for 
insulin. In this study, 4 episodes that octreotide was adminis-
tered simultaneously with glucose solution were excluded. The 
maximum level of blood sugar achieved was 169mg/dL.
Only 3/17 (17.6%) patients presented rebleeding. As 
shown in Table 2, one patient was not submitted to endo-
scopic treatment (patient 1). In this patient, rebleeding oc-
curred from the esophageal varix on day 4 of treatment and 
was controlled by band ligation. The other two patients had 
undergone band ligation. One patient with Child C cirrhosis 
(patient number 2) maintained bleeding throughout the 
treatment and died. The other patient (patient number 3) 
presented bleeding on day 8 after the end of infusion.
No significant differences in the occurrence and the de-
termination of site of active bleeding were observed between 
patients who received octreotide and those who did not receive 
the medication before the endoscopy. In the patients who re-
ceived octreotide the active bleeding was present in 2 and the 
site of bleeding was determined in 9. In patients that did not 
receive octreotide before endoscopy, the active bleeding was 
present in 3 and the site of bleeding was determined in 7.
Comparison of patients who received bolus and mainte-
nance doses of octreotide and those who received only the 
maintenance dose showed no significant differences regard-
ing mean transfusion volume, mean drop in hemoglobin 
levels, duration of octreotide treatment or hospital length 
of stay (Table 3).
When bleeding episodes were compared between cirrhotic 
and non-cirrhotic patients, a higher drop in hemoglobin 
levels, a higher transfusion volume and a longer duration 
of hospital stay were observed in cirrhotic patients, but this 
difference was not significant. The time of use of octreotide 
was similar in the two groups (Table 4).
Treatment failure was observed for 2/6 bleeding episodes 
in cirrhotic patients and for 1/20 episodes in non-cirrhotic 
ones (Fisher’s exact test, p=0.12).  Frequency of side ef-
fects (hyperglycemia) was lower in cirrhotic patients, but 
no significant difference was observed between groups 
(p=0.38) (Table 5).
Discussion
The frequency of gastrointestinal bleeding in children 
with portal hypertension is higher in those with extra-
hepatic portal vein obstruction than in cirrhotic patients. 
Portal vein obstruction is responsible for about 70% of all 
pediatric patients with portal hypertension(11). In the present 
study, 64.7% of the patients had portal hypertension due to 
extra-hepatic portal vein obstruction and presented 20/26 
(76.9%) episodes of gastrointestinal bleeding.
Patient 1 Patient 2 Patient 3
Site of bleeding Esophageal varices 
F3LsBcRs+
Esophageal varices 
F3LiBcRs+
Esophageal varices 
F2LsBcRs+
Endoscopic treatment No Band ligation Band ligation
Period of rebleeding Day 4 of treatment Throughout treatment (2 days) Day 8 post-treatment
Etiology EHPVO Hepatitis C AIH
EHPVO: extrahepatic portal venous obstruction; AIH: autoimmune hepatitis; F2: medium caliber varices; F3: large caliber varices; Li: locus inferior 
of esophagus; Ls: locus superior of esophagus; Bc: blue color of varices; Rs+: red sign present.
Table 2 - Site of bleeding, endoscopic treatment, etiology of portal hypertension, and period of rebleending in three rebleeding patients
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Active bleeding was observed during the endoscopic exam in 
only 5/26 (38%) bleeding episodes analyzed at this study. De-
spite the small number of patients, no statistical differences were 
observed between episodes previously treated with octreotide and 
those untreated. This finding supports the hypothesis that bleed-
ing ceases spontaneously in many cases. D’Amico et al(12) reported 
spontaneous cessation of bleeding in 40 to 50% of adult patients 
with upper gastrointestinal bleeding due to portal hypertension. 
In children, Eroglu et al(13) noted the absence of active bleeding 
during endoscopic examination in 71% of episodes that occurred 
in patients under treatment with octreotide, but the percentage 
of cases in which bleeding cessation was spontaneous or secondary 
to the use of the medication could not be determined. 
Some studies show that bolus administration of octreotide to 
clinically stable cirrhotic patients causes systemic vasoconstric-
tion, a transient decrease in the hepatic venous pressure gradient 
Cirrhosis Hemoglobin Decline
Length of stay in 
hospital (days) Time of use (days)
Transfusion 
volume (mL/kg)
Yes n 5 6 6 4
Mean 4.2 8.3 3.2 31.5
Median 4.5 7.5 2.5 29.8
P25 2.5 4.7 2.0 17.2
P75 5.7 11.5 5.0 47.4
No n 19 20 20 13
Mean 3.3 6.4 3.1 21.4
Median 3.1 5.5 3.0 14.5
P25 2.3 4.25 2.25 9.9
P75 3.9 8.0 4.0 26.1
p* 0.33 0.3 0.97 0.13
Table 4 - Blood volume transfused, decline in hemoglobin levels, time of use of octreotide and duration of admission in cirrhotic 
and non-cirrhotic patients
*Mann-Whitney test.
Cirrhotic Non-cirrhotic p*
Blood transfusion 4/6 13/20 1.0
Active bleeding at endoscopy 1/6 4/20 1.0
Treatment failure 2/6 1/20 0.123
Side effects 1/6 8/20 0.380
Table 5 - Distribution of the clinical data of bleeding episodes according to the presence or absence of liver cirrhosis
Bolus dose Hemoglobin Decline
Duration of 
admission (days) Time of use (days)
Blood transfusion 
volume (mL/kg)
Yes n 19 20 20 13
Mean 3.4 7.1 3.2 20.7
Median 3.4 6.0 3.0 15.0
P25 2.6 5.0 3.0 9.9
P75 4.5 9.0 4.0 30.3
No n 5 6 6 4
Mean 3.8 6.0 2.8 33.5
Median 3.1 4.5 2.0 19.8
P25 2.1 3.7 1.3 12.9
P75 5.7 7.5 4.7 67.9
p* 0.8 0.1 0.3 0.4
*Mann-Whitney test.
Table 3 - Blood volume transfused, decline in hemoglobin levels, time of use of octreotide and duration of admission according to 
the administration or not of a bolus dose of the drug
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and a significant reduction of cardiac output(3,5). However, in the 
present study, the administration of a bolus dose did not modify 
significantly the mean transfusion volume, mean hemoglobin 
decline, duration of octreotide treatment or hospital stay. 
The only side effect detected during the administration of 
octreotide was hyperglycemia. In a meta-analysis on octreotide 
for acute esophageal variceal bleeding, Corley et al(14) observed a 
frequency of hyperglycemia ranging from 0 to 23%. In another 
meta-analysis, Bañares et al(15) compared endoscopic treatment 
with endoscopic treatment combined with pharmacological 
therapy for the control of acute variceal bleeding and found 
that hyperglycemia was the only adverse effect in the studies 
analyzed, with this side effect being significantly more frequent 
in the group of patients that underwent pharmacological treat-
ment. However, the use of somatostatin and its derivatives (e.g., 
octreotide) was considered to be safe in view of the finding that 
none of the patients required discontinuation of therapy(15).
Regarding the three patients who presented rebleeding, 
two had cirrhosis classified as Child C and the other under-
went endoscopic treatment until the occurrence of rebleed-
ing. Probably, the episodes of rebleeding were mainly related 
to the severity of the underlying disease and to the need of a 
definitive treatment rather than a medication effect. 
Comparison of the bleeding episodes between cirrhotic 
and non-cirrhotic patients showed that the drop in hemo-
globin levels, the blood transfusion volume, and hospital 
stay were slightly greater and in cirrhotic patients, although 
no statistical significance was observed, probably due to the 
small number of patients in groups . This finding is probably 
related to the r clinical severity of patients with cirrhosis 
who, in addition to impaired hepatic function, often present 
malnutrition and impaired general health.
Comparison of the present results with other studies is limit-
ed by the characteristics of the series, i.e., a pediatric population 
in which the main cause of upper gastrointestinal bleeding due 
to portal hypertension was extra-hepatic portal vein obstruction. 
Most studies evaluating octreotide were conducted on adults 
with cirrhosis and patients with gastrointestinal bleeding not 
related to portal hypertension(16). Similar results in terms of the 
decline in hemoglobin levels, transfusion volume and duration 
of treatment were reported in a study of pediatric patients(13). 
The present report has limitations regarding its retro-
spective design and a small number of patients, however, it 
differs from international series due to the lower frequency 
of rebleeding, treatment failure and mortality. The effect 
of cirrhosis and hepatic insufficiency on the occurrence of 
rebleeding should be investigated in multicenter studies of 
patients with different demographic characteristics.  Larger 
cohort studies are necessary to determine the benefits of 
combined or single treatment with octreotide in children, 
irrespective of the etiology of portal hypertension.
The use of octreotide in children and adolescents with 
portal hypertension with or without cirrhosis was considered 
safe. The drug seems to be effective in controlling acute 
bleeding in patients with portal hypertension, irrespective 
of etiology and the infusion schedule.
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